5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine.
Shu NiuKhalid A AlkhuzamDawei GuanTianze JiaoLizheng ShiVivian A FonsecaNeda LaiteerapongMohammed K AliDesmond A SchatzSerena Jingchuan GuoStephen R BenoitPublished in: Diabetes, obesity & metabolism (2023)
With the use of the BRAVO diabetes model, tirzepatide and semaglutide exhibited potential to reduce the risk of macrovascular and microvascular complications among individuals with type 2 diabetes, compared with insulin glargine in a 5-year window. Based on the current modelling assumptions, tirzepatide (15 mg) may potentially outperform semaglutide (1 mg). While the BRAVO model offered insights, the long-term cardiovascular benefit of tirzepatide should be further validated in a prospective clinical trial.